THERALASE TECHNOLOGIES INC. (TSX.V: TLT)
|
|
- Willa Atkins
- 5 years ago
- Views:
Transcription
1 COMPANY RESEARCH: LIFE SCIENCES THERALASE TECHNOLOGIES INC. (TSX.V: TLT) Cancer treatment with 100% success on mice; Also a pain treatment system; Successful tests in mice indicate potential for Breakthrough status with FDA; Human trials starting soon. Overview Theralase Technologies Inc. (TSX.V:TLT) (OTCMKTS:TLTFF) (FRA:TXT) has a simple value proposition: a cure for cancer. If there is one thing that might be considered the most valuable and important discovery in this century, it is without doubt a cure for cancer. There is no one who has not been affected in some way by the most lethal disease of our lifetimes. My grandfather died of prostate cancer, my grandmother of lung cancer, my uncle of prostate cancer when he was in his early 50s. And the pretenders to this holiest grail of the life sciences have been legion. To date, the results have been dismal at best. In an era when deaths from cancer are expected to rise dramatically, the lack of progress is nothing short of alarming. The number of people who are qualified to analyze and verify the data are obviously few in number, and so I certainly don t make any claims of being capable of assessing Theralase s technology. My rationale for participating in this company as an investor is straightforward: If it works, it will be huge. If it doesn t, then I take that risk willingly and on a calculated basis, knowing I could lose my money. But it s the possibility this company represents that excites me, albeit cautiously so. The Rise of Photo Dynamic Compounds The essence of Theralase s cancer treatment is a class of drugs called Photo Dynamic Compounds (PDCs). These Shares Outstanding (Basic)...~65M Fully Diluted...~86M Market Cap...~$25M Debt...NIL 52 Week Range...$ $0.56 Average Volume (3 month)...194,769 Focus...Cancer Therapy, Pain Mitigation Therapy Operating in:...canada, United States are drugs which, when exposed to very specific types of light, become active in destroying cancer cells. The process is marginally invasive, in that the only invasiveness to tissue is the introduction of the light source, typically through a optical fibre. The PDC is introduced to the organ or area of the body where the cancer has localized and then once absorbed into the cancer cells, the PDC is activated by light from the optical fibre. The PDCs become cytotoxic (cell destructive) when activated by the light sources in the presence of oxygen. The Theralase PDCs have the added unique ability that they are able to be cytotoxic not only in the presence of oxygen, but more importantly in the absence of oxygen, where cancer cells are known to thrive. Tumour induced in animal (BALB/c mice ) with tumour reaching mm in size.mice have survived 20 months cancer free after only 1 PDC treatment (Essentially the rest of their natural lives) Tumour induced in animal (BALB/c mice ) with tumour reaching mm in size. Mice have survived 20 months cancer free after only 1 PDC treatment (Essentially the rest of their natural lives) According to the company s recent press release: Theralase Technologies Inc. reported today (February 13, 2014) that a recently published scientific paper 1
2 2 demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (S. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer commonly presents in solid cancers, such as brain, bladder, breast, lung and prostate. Hypoxic cancers are extremely aggressive, resistant to standard therapies (chemotherapy and radiation therapy), and thus are very difficult to destroy. Tumor hypoxia is known to play a role in cancer metastasis (spread) and resistance to therapy, as well as the ability of cancer cells to escape destruction by the immune system. The evidence supporting the Theralase PDC technology represents a potential solution for hypoxic cancers. In our work, we described a family of Theralase PDCs that have shown an ability to switch their photoreactivity from a Type II reaction (oxygen dependent) to a Type I (free radical mediated) reaction. This is strategic to the Company in that a Type I reaction is unique and opens the opportunity of using the PDCs beyond sterilization and the treatment of superficial cancerous lesions to the treatment of harder to treat hypoxic tumours. All very well and good, but what has been the reaction in the scientific community? Peer Review Process Validates Theralase There have been three peer reviewed papers published that validate the company s statements of efficacy in these compounds ability to annihilate bacteria, viruses and cancer cells. One, by the American Society for Microbiology, published in February 2013, concluded: destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25). The ability for the PDC technology to be effective in low oxygen environments is considered to be an essential factor in the recurrence and progression of non-muscle invasive bladder cancer. This form of disease represents up to 75% of newly diagnosed bladder cancer cases accounting for more than 386,000 cases and 150,000 deaths annually worldwide, said Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. Dr. Mandel continued: The abnormal decrease or the lack of oxygen supply to cells and tissues is called hypoxia and There is a recent recognition that Ru(II) (Ruthenium compounds) complexes might prove useful as Photo Dynamic agents, particularly for virulent strains of infectious disease including gram-negative pathogens, owing to their intrinsic cationic charge. However, these Photo Sensitizers (PSs) will continue to suffer from the inability to destroy microbial targets at low oxygen tension, and since precise knowledge of oxygen tension in a wound, for example, is not possible, the best PDI agent will be one that can function regardless of oxygen tension. In this report, we have demonstrated that it is possible to instill Type I activity into a simple mononuclear Ru(II) complex using principles derived from coordination and materials chemistry. This activity was outlined in Staphylococcus aureus (S. aureus or SA) and Methicillin Resistant Staphylococcus aureus (MRSA) in hypoxia, and proved to be as effective, or more
3 3 effective in some cases, than normoxia. Equally important, the TLD1400 series is active at concentrations of over 3 orders of magnitude lower than the gold standard PS Methylene Blue (MB). This photodynamic potency applies to bacterial cells and cancer cells alike, and therefore, represents a new paradigm for designing Type I PS using Ru(II) that extends to other clinical applications. Note that the press release quoted previously addresses the concern of the inability to destroy microbial targets at low oxygen tension. In another published paper The Royal Society of Chemistry stated To improve the effective elimination of tumours by Photo Dynamic Therapy (PDT), PSs with a range of 10 photophysical and photobiological attributes must be developed, including: specific cellular and subcellular targeting, maintenance of high cytotoxic load in oxygendepleted environments and activation by light with necessary penetration depths, but sufficient photon quantum energy to produce cytotoxic Reactive Oxygen Species (ROS). Thus, an ideal PS should be a chemically pure compound with high tissue and cellular selectivity that (i) exhibits long wavelength absorptions preferably at wavelengths (>670nm) to provide larger tissue penetration depths (e-1 attenuation depth), (ii) possesses a short injection to light time interval (drug-light interval), (iii) has low dark toxicity, but strong photo cytotoxicity, and (iv) rapidly clears from the system. This precisely describes Theralase s TLD1400 series PDCs. Breakthrough Status All this is good news. From an investment standpoint, the sooner this gets to human trials, the sooner we see results for human cancers and the sooner we might realize a return on investment. During an interview, I asked how long that process might take. According to Theralase CEO Roger Dumoulin-White: Well, that specifically depends on the regulatory approval authorities like Health Canada and the Food and Drug Administration (FDA). The FDA, to their credit, has in July of 2012 created something called Breakthrough Status. This is in addition to their Fast Track approval that they have had in place since 2002 to encourage research and development into therapies and potential cures for orphan diseases (less than 200,000 individuals afflicted with the disease) In the United States, the Rare Diseases Act of 2002 defines rare disease strictly according to prevalence, specifically any disease or condition that affects less than 200,000 persons in the United States, [2] or about 1 in 1,500 people. This definition is essentially like that of the Orphan Drug Act of 1983, a federal law that was written to encourage research into rare diseases and possible cures.1 So Fast Track approval allows pharmaceutical and biotech companies a faster route through the FDA process in order to develop drugs or technology that could work on conditions that are not as common. But in July of 2012, they came out with what s called Breakthrough Status, which provides an even faster route through the regulatory quagmire. With Breakthrough Status there are three conditions that must be met to achieve this approval: 1) The treatment must treat a deadly disease and clearly cancer qualifies in this definition. 2) Existing therapies have not been able to effectively treat the condition. Bladder cancer has not had any new drugs approved for it for over 15 years, so progression in the destruction of this disease has stagnated. 3) Demonstrate safety and efficacy data, which is a substantial improvement over existing therapies, even on a small population. On July 9, 2012 the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed. FDASIA Section 902 provides for a new designation Breakthrough Therapy Designation. A breakthrough therapy is a drug: intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing
4 4 therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug. For more information, see: regulatoryinformation/legislation/ federalfooddrugandcosmeticactfdcact/ significantamendmentstothefdcact/fdasia/ucm htm So a small Phase 1 / 2a clinical trial, which was successful in demonstrating the safety, tolerability and efficacy of the treatment could potentially qualify for Breakthrough Status. If the company was granted Breakthrough Status, the FDA works hand in hand with the company to minimize the time to commercialization to a bare minimum. So if all the stars are in alignment, continued Demoulin- White, after completion of our preclinical research this year, successful completion of our Phase 1 / 2a human clinical trial in 2015, and we are lucky enough to successfully petition the FDA to achieve Breakthrough Status, our PDC technology could be available to treat patients suffering from bladder cancer by early If we were not able to achieve Breakthrough Status, we would still be eligible for Fast Track approval, which even with a Phase 2B or Phase 3 clinical study, would only delay commercialization an additional two to five years. studies or execute a co-development agreement with big pharma to allow them to partner with us through to commercialization. So the answer to your question really lies in what the regulators decide,, if they support us two years from today on the shortest timeline, if they request more data up to seven years on a longer timeline. That is, if the company isn t taken out in an acquisition sooner. Valuations for companies with effective cancer treatments are substantial. Big Pharma is on the Hunt Major biotechnology and life sciences companies are always on the lookout for promising therapies in the cancer space. Reuters reported February 17 that Novartis AG (NYSE:NVS) stated it will buy U.S.-based CoStim Pharmaceuticals Inc., a privately held biotechnology company focused on harnessing the immune system to eliminate immuneblocking signals from cancer, for an undisclosed price. The Swiss drugmaker said the move follows increasing evidence pointing to the role of the immune system in controlling cancer. The table below shows a sampling of pharma deals in the last few years: In parallel to this strategy, we would be actively looking for a co-development partner, most likely big pharma in order to aid in the distribution of this revolutionary technology to locations throughout North America and in due course the world. So there are a number of different commercialization strategies that will depend on FDA regulatory approval status, but the fastest path to commercialization would be achieved if we were successful in being granted Breakthrough Status, allowing us to introduce the technology commercially almost immediately; however, if we were not successful on this front, we could elect either to raise more capital in order to complete further clinical Theralase Therapeutic Laser Platform Technology: As if a cure for cancer wasn t enough to carry this company to a touchdown for life sciences investors, almost equally
5 5 substantial in terms of impact on future revenues is the company s laser treatments for pain that is already in wide spread use. Theralase has over 800 of these systems installed and in use in Canada, and over 400 more in the U.S. and internationally. The product is the TLC-1000 Cold Laser System, which Theralase has developed over 17 years and has been based on solid clinical research. There have been over 1 million patients successfully treated and thousands of Theralase lasers have been sold to health care practitioners around the world. According to the company s web site: The Theralase super pulsed laser system can penetrate up to 4 into tissue, to promote cellular regeneration at the source of the injury and is the only laser on the market known to activate all three cellular pathways. www. theralase.com Theralase is migrating the business from a one-time capital equipment purchase model, where they sell the units for a one-time cost in the $16,000 range, to a recurring revenue model, where they will lease the units to health care clinics, hospitals and practitioners for $500 per month, in perpetuity. With each unit generating on average, $10,000 a month for its customers, the new model is expected to substantially increase its market share for such devices worldwide. The company is targeting $6.6 million in annual revenue from the first 400 such devices placed, providing a 20X return on investment for its clients is the Year of Expansion for Theralase The company has an ambitious year planned. Targeting the $100 billion annual US market for pain mitigation, Theralase will launch its next-generation patented TLC-2000 therapeutic laser system in the fourth quarter of this year. It plans to launch sales offices in Calgary, Vancouver, New York, Los Angeles, Tampa, Chicago and Houston in 2014 and 2015 and will deploy an aggressive sales strategy seeking to displace competitive technologies in these markets with its superior products and revenue structures for clients. Conclusion Theralase is thus far under the radar of major pharmaceutical corporations, but with the recent breakthroughs in its PDC therapies in low-oxygen environments, the lid is coming off this story quickly. The company s serious potential is offset by the normal risk associated with an earlier stage therapy like the TLD-1400 series of compounds, that of proving their safety and efficacy in human clinical testing. On the plus side of their potential success is that there have been two previously FDA approved PDC drugs; specifically: Aminolevulinic Acid (ALA) and Photofrin, which have been FDA approved for actinic keratosis (Rough, scaly patches of skin that are considered precancerous) and esophageal cancer, respectively. Theralase to their credit has tested their new TLD-1400 series of PDCs against these two FDA approved drugs and have demonstrated in documented scientific research that they are 668,000x more effective than ALA and 198x more effective than Photofrin, while delivering a treatment with virtually no side effects. This bodes well for a successful Phase 1/2a clinical trial. The second plus in their corner is that their TLD-1400 series of drugs are nuclear acting, meaning that they enter cancer cells and lock onto the DNA of the cell, unlike ALA and Photofrin. When light activated, this new class of PDCs destroy the cancer cell by what is called apoptosis or natural cell death, basically the cell dies of natural causes. The beauty of nuclear acting drugs is that it doesn t matter if the cancer cell came from a mouse, an ostrich, a dolphin or a human, they are all destroyed with the same efficacy and safety profile, as these are all mammallian cells, known collectively as eukaryotes. So the multi-billion dollar question is not what if the Theralase technology doesn t work as well on humans as it does on mice, but more appropriately when will Theralase deliver us positive clinical study results. 1 Wikipedia Rare Disease 2 US Department of Health and Human Services
Theralase Presents Dosimetry Planning at International World Congress
Theralase Presents Dosimetry Planning at International World Congress Toronto, Ontario June 13, 2017, Theralase Technologies Inc. ( Theralase or the Company ) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology
More informationTheralase Therapeutic Laser Technology Enhances Cancer Destruction
Theralase Therapeutic Laser Technology Enhances Cancer Destruction Toronto, Ontario November 27, 2017, Theralase Technologies Inc. ( Theralase or the Company ) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationMedifocus, Inc. OTCQX: MDFZF TSXV: MFS.
Medifocus, Inc. OTCQX: MDFZF TSXV: MFS www.medifocusinc.com Except for historical information, the statements made in this presentation are forward-looking statements involving significant risks and uncertainties.
More informationOragenics Shareholder Update
January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationOFFICE OF RESEARCH PUBLICATIONS
YOU ARE VIEWING A.PDF FILE FROM THE OFFICE OF RESEARCH PUBLICATIONS Please adjust your settings in Acrobat to Continuous Facing to properly view this file. Thank You. Tackling Tooth Oragenics hopes people
More informationAfter simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up.
New Medical Device Company Addresses Two Very High Demand Markets with its Proprietary Products. Trader Tracks likes this company as they provide reasonably priced equipment and testing while medical costs
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationHIGH CLINICAL ACCEPTANCE OF METVIX PDT
HIGH CLINICAL ACCEPTANCE OF METVIX PDT PhotoCure ASA Second Quarter Report 2002 Highlights: Marketing of Metvix PDT in Europe Progressing as Planned Positive Phase III Clinical Results in the Treatment
More informationMedifocus, Inc. OTCQX: MDFZF TSXV: MFS
Medifocus, Inc. OTCQX: MDFZF TSXV: MFS www.medifocusinc.com Develops and commercializes minimally invasive focused heat thermotherapy systems for the treatment of cancer and other diseases January 2014
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationPROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION
Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition
More informationA company developing innovative, high-impact drugs for cancer
A company developing innovative, high-impact drugs for cancer Investor Briefing March 2019 ASX: KZA NASDAQ : KZIA Twitter: @KaziaTx Forward-Looking Statements This presentation contains forward-looking
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationHOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK
HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of
More informationCANCER HAS BEEN AROUND
For decades, drug companies have been spending billions of dollars and countless hours on researching and developing treatments and cures for cancer. The reason is easy to understand. Cancer is the second-leading
More informationDRUG DEVELOPMENT. How do drugs become available for prescription?
DRUG DEVELOPMENT How do drugs become available for prescription? OUTLINE Birth Idea, Chemistry, Pharmacology. Obtaining a patent. Passing regulatory hurdles (IND and NOC) Pre-clinical trials and data.
More informationMAGFORCE AG FIGHTING CANCER WITH NANO MEDICINE
MAGFORCE AG FIGHTING CANCER WITH NANO MEDICINE 2014, Berlin, Germany 2 EXECUTIVE SUMMARY Company Profile Headquartered in Berlin, Germany Current Management Team: B. Lipps, H. Tawfik, C. von Volkmann Frankfurt
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationFor personal use only
Targeted DEP shows sustained superior performance in ovarian cancer model Melbourne, Australia; 2 February 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the final results of the preclinical
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationWednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address
Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday
More informationCold Laser Program ML830
Cold Laser Program ML830 The Microlight ML830 Cold Laser, started everything 25 years ago. It was developed in 1985, by leading european doctors and engineers. The laser was brought to the USA in 1990,
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationVapor Shark Franchising BE THE BEST IN YOUR INDUSTRY
FRANCHISING 2017 2 BE THE BEST IN YOUR INDUSTRY VS VS 3 WHAT IS VAPOR SHARK? Vapor Shark is an industry-leading manufacturer and distributor of premium electronic cigarette devices, e-liquids and accessories.
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationInnovator Case Studies: Oncology Networks
Innovator Case Studies: Oncology Networks J. Ike Nicoll Chief Executive Officer Cancer Clinics of Excellence Alan Armer, Ph.D. Vice President, Research & Development Catholic Health Initiatives Cancer
More informationPhotoCure ASA Presentation First quarter 2005 May 3, 2005
PhotoCure ASA Presentation First quarter 2005 May 3, 2005 Obtaining milestones and building value Hexvix Approval in 27 EU/EEA countries, working on national approvals Ongoing phase III study for extended
More informationYour Partner in Healing
Your Partner in Healing Euromed provides all functions necessary for market-ready hydrocolloid wound dressings. With fully integrated services, Euromed is one of a select few custom hydrocolloid manufacturers
More informationMedifocus, Inc. OTCQX: MDFZF TSXV: MFS
Medifocus, Inc. OTCQX: MDFZF TSXV: MFS www.medifocusinc.com Develops and commercializes minimally invasive focused heat thermotherapy systems for the treatment of cancer and other diseases August 2013
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationPRESENTATION. AGM 27 th OCTOBER 2015 ASX: PAA ACN
PRESENTATION AGM 27 th OCTOBER 2015 ASX: PAA ACN 094 006 023 Disclaimer This presentation does not constitute investment advice. Neither this presentation nor the information contained in it constitutes
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationIn reality the PDT mechanism requires that three things be together in the body at the same time. These three things are oxygen, chromophore
The Real Skinny on Green Light Therapy This is a dry read...but try and make it through! I've underlined a couple of sentences that I really want you take in. 1. Overview. Current phototherapy for acne
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationPhoenix Molecular Designs
Phoenix Molecular Designs DESIGNING PRECISE THERAPEUTICS TO REVOLUTIONIZE TREATMENT Our Team Dr. Sandra Dunn, Ph.D. Dr. Anna Stratford, Ph.D. Dr. Aarthi Jayanthan, Ph.D. Dr. Zaihui Zhang CEO, CSO UBC Professor
More informationFor personal use only. A new company with: a new technology platform for cancer drug development a new management team a new Board
A new company with: a new technology platform for cancer drug development a new management team a new Board Disclaimer This presentation is confidential and is not an offer or a recommendation or intended
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationRestoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected.
Restoration JDRF is turning Type One into Type None Type 1 diabetes (T1D) is an extraordinarily complex disease. Finding the cure a short-term clinical intervention, with minimal side effects, after which
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationItamar Medical. December Investors Presentation.
Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationIntroductory Presentation
Introductory Presentation WEEK 6 WEEK WEEK 1 2 WEEK 5 WEEK 3-4 STRUCTURED HORIZON WELCOME TO THE FAMILY FRANCHISE AGREEMENT DELIVERY PERSONALIZED FRANCHISE AGREEMENTS DELIVERED DAY OF DISCOVERY MEET THE
More informationProduction Management of Sterile Medical PDT Probes
Production Management of Sterile Medical PDT Probes Koichi Akiyama, Takeshi Akimoto [Summary] One in two Japanese living today can expect to suffer from a malignant tumor (cancer), which has been the leading
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationIntroducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST)
Introducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST) CED Life Science Conference February 27, 2018 Almost 40% of us will be diagnosed with cancer at some point in our lives
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationCorcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
More informationHeartSciences MyoVista High Sensitivity ECG Technology LAUNCH Key Messages and Q&A Updated: August 17, 2017
HeartSciences MyoVista High Sensitivity ECG Technology LAUNCH Key Messages and Q&A Updated: August 17, 2017 Key Messages Message 1: Diagnostic Gap Detection of Asymptomatic Patients Physicians do not have
More informationInnovative Nuclear Receptor Modulation Medicine
Innovative Nuclear Receptor Modulation Medicine Dale C Leitman, M.D., Ph.D. Isaac Cohen, O.M.D., Ph.D. October 2015 Corporate Mission Iaterion, Inc. is Developing Novel Pharmaceutical Nuclear Receptor
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationCPRIT Overview. Cancer Centers Administrators Forum April 4, 2016
CPRIT Overview Cancer Centers Administrators Forum April 4, 2016 CPRIT s Unique Role in the Fight Against Cancer Overview: Created by the Texas Legislature and citizens in 2007 $3 billion over 10 years
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationCochlear Implants - Medical Devices Pipeline Assessment, 2016
Cochlear Implants - Medical Devices Pipeline Assessment, 2016 Cochlear Implants - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been marketing business and market research reports from selected
More informationProgram Priorities 2018
Program Priorities 2018 Blank Page 2 CONTENTS: About CPRIT Program Priorities Project...Page 5 Process to Develop Program Priorities...Page 6 Scope of Program Priorities Project...Page 6 CPRIT s Long-Term
More informationDendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity
Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity Melbourne, Australia; Wednesday 11 September 2013: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved
More informationMDxHealth. Strong outlook for Research Note.
Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February
More informationDear Colleagues: January 3, 2018
Dear Colleagues: January 3, 2018 We have launched the nationwide initiative of Project Dental America designed to reduce the frequency and severity of periodontal disease and its 50+ associated medical
More informationCannabis Regulations Response and Update on Cannabis Legalization
Page 1 of 5 EXECUTIVE SUMMARY On 2018 October 17, Bill C-45, The Cannabis Act, came into force legalizing non-medical cannabis in Canada. Non-medical cannabis is now legal in limited forms, including dried
More informationBrochure More information from
Brochure More information from http://www.researchandmarkets.com/reports/2375238/ Breast Imaging Technologies Market (Digital Mammography,3D Breast Tomosynthesis, Breast MRI, Breast Ultrasound, Molecular
More informationRobotic Spine Surgery [TASE]: MZOR
Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.
More information(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018
(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health December 2018 Safe Harbor Statement All statements in this presentation that are not based on historical fact are forward looking statements.
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More information概美科技. GuideMia Technologies, LLC Sept
概美科技 info@guidemia.com GuideMia Technologies, LLC Sept 2017 +1 714 391 2739 Offering worldwide dentists and dental labs image guided implant and digital orthodontics solutions and services that change
More informationINTRODUCTION PREVIOUSLY FUNDED PROJECTS
INTRODUCTION Each year in the United States, more than 1.6 million people are diagnosed with cancer and more than half a million die from this terrible disease. And each year, our researchers spend thousands
More informationInSite Vision DOUBle Phase 3 Clinical Program
InSite Vision DOUBle Phase 3 Clinical Program AzaSite Plus (ISV 502) & DexaSite (ISV 305) For the Treatment of Blepharitis May 2011 Today s s Discussion Overview & Opportunity Phase 3 Trial Design/SPA
More informationEARLY DETECTION: THE NEW CANCER PARADIGM
EARLY DETECTION: THE NEW CANCER PARADIGM By Dr. Amit Kumar and Robert A. Berman March 1, 2016 A seemingly healthy patient walks into the doctor s office for a routine checkup. The doctor says, I have good
More information### About Bharat Biotech
Press Release Bharat Biotech Bharat Biotech Launches Typbar-TCV, world s first clinically proven typhoid conjugate vaccine for infants 6 months & older and Adults The new vaccine brings hope to millions
More informationVivaGel BV. Product Information and Independent Market Research 30 APRIL 2018 STARPHARMA HOLDINGS LIMITED ASX:SPL; OTCQX:SPHRY
VivaGel BV Product Information and Independent Market Research 30 APRIL 2018 STARPHARMA HOLDINGS LIMITED ASX:SPL; OTCQX:SPHRY Important notice and disclaimer This document contains certain forward-looking
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationUCT Conference Incoming President s Speech Delivered by UCT President Chris Phelan July 4, 2018
UCT Conference 2018 - Incoming President s Speech Delivered by UCT President Chris Phelan July 4, 2018 Change is the law of life. Those who look only to the past and present are certain to miss the future.
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationMDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationCan you please describe your role within the company? How did you get to be in this position, and what are your responsibilities?
Immunservice questionnaire: 1. Please can you give us a short description of what your firm does? What healthcare areas does your firm specialise in? Immunservice is the expert for innovative well-tolerated
More informationJeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine.
Jeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine. 1 2 On April 30 the VU and VUMC transition was completed and we
More informationReady for a Fundraising Breakthrough?
Ready for a Fundraising Breakthrough? Fundraising never looked so good. Although I have formulated thousands of products during my 40+ years in the skincare manufacturing industry, I have never seen a
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More information